scispace - formally typeset
R

R Matthew Chico

Researcher at University of London

Publications -  53
Citations -  2104

R Matthew Chico is an academic researcher from University of London. The author has contributed to research in topics: Malaria & Medicine. The author has an hindex of 17, co-authored 40 publications receiving 1327 citations.

Papers
More filters
Journal ArticleDOI

Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016.

TL;DR: The study highlights the need to expand data collection efforts at country level and provides an initial baseline for monitoring progress of the World Health Organization global health sector strategy on sexually transmitted infections 2016–2021.
Journal ArticleDOI

Prevalence of malaria and sexually transmitted and reproductive tract infections in pregnancy in sub-Saharan Africa: a systematic review.

TL;DR: In this paper, a systematic review and meta-analysis of malaria and STI/RTI prevalence estimates among pregnant women attending antenatal care facilities in sub-Saharan Africa was conducted.

Prevalence of Malaria and Sexually Transmitted and Reproductive Tract Infections in Pregnancy in Sub-Saharan Africa

TL;DR: The dual prevalence of malaria and STI/RTIs in pregnancy among women who attend antenatal care facilities in sub-Saharan Africa is considerable, with the combined prevalence of curable STIs/RTI being equal to, if not greater than, malaria.
Journal ArticleDOI

Factors that influence vaccination decision-making among pregnant women: A systematic review and meta-analysis

TL;DR: The effect of an HCP recommendation during an outbreak, whilst still powerful, may be muted by other factors and public health campaigns which centre on the protectiveness and safety of a maternal vaccine rather than disease threat alone may prove beneficial.
Journal ArticleDOI

Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy

TL;DR: Key in vitro and in vivo evidence of azithromycin and chloroquine activity against Plasmodium falciparum and PlasModium vivax is summarized, as well as the anticipated secondary benefits that may result from their combined use in IPTp, including the cure and prevention of many sexually transmitted diseases.